Result: Risk Minimisation Materials for medicines starting with the letter B

Bavencio

Merck - Pfizer

Bavencio 20 mg/ml concentrate for solution for infusion (avelumab) – Patient Information Brochure

Patient Information Brochure - Important safety information to minimise the risk of immune-related side effects - myasthenia gravis update

Belkyra

Allergan Ltd

INJECTOR’S GUIDE FOR THE SAFE USE OF BELKYRA

This guide provides important information on the safe and effective use of BELKYRA (deoxycholic acid) in order to minimise the risk of injection site nerve injury and associated motor neuropraxia, injection site skin ulceration and necrosis. The guide contains: 1. Information on how to report suspected adverse drug reactions 2. Figures to show anatomical structures of the neck/ key anatomic landmarks of the cervicomental region/ submental fulness scale 3. Checklist for the administration of Belkyra 4. Procedure checklist

For Healthcare Professionals

Benepali

Biogen Biosimilars

Benepali Healthcare Professional Training Guide

Brief Training on additional risk minimization measures for HCPs

For Healthcare Professionals

Benepali Patient Alert Card

PAC contains important information that patients need to be aware of.

Benepali Quick Reference Guide for pre-filled pen

This guide is designed to offer quick reference on how to inject safely and effectively.

Benepali Quick Reference Guide for pre-filled syringe

This guide offers quick reference on how to inject safely and effectively.

Beovu

Novartis Pharmaceuticals UK Ltd

Beovu (Brolucizumab) - Patient Guide to Therapy - for patients

This guide contains important information about Beovu (Brolucizumab) why its been prescribed, side effects and their potential risks.

Bimizza

Morningside Healthcare Ltd

Checklist for Prescribers - Bimizza 150 microgram/20 microgram Tablets

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations. •Thromboembolism (e.g. deep vein thrombosis, pulmonary embolism, heart attack and stroke) is a rare but important risk with use of a CHC.

For Healthcare Professionals

Important Information for Women Leaflet - Bimizza 150 microgram/20 microgram Tablets

All women should understand: the small risk of blood clots with combined hormonal contraceptives; what other conditions increase the risk of a blood clot; the signs and symptoms of a blood clot; and when you need to tell a healthcare professional that you are using a combined hormonal contraceptive. Although the risk is small, blood clots can be serious. This information will help you minimise your risk.

Patient Alert Card - Bimizza 150 microgram/20 microgram Tablets

IMPORTANT INFORMATION FOR WOMEN ABOUT RISK OF BLOOD CLOTS WITH COMBINED HORMONAL CONTRACEPTIVES

Bivalirudin

Accord Healthcare Limited

Bivaluridin Accord dosing and administration instruction for medically managed ACS patients with urgent or early intervention

This document will serve as a guide to HCP on dosing and administration of Bivaluridin Accord for medically managed ACS patients with urgent or early intervention.

For Healthcare Professionals

Bivaluridin Accord dosing and administration instruction for PCI and Primary PCI

This document will provide instruction for dosing and administration of Bivaluridin Accord following PCI and primary PCI

For Healthcare Professionals

Direct Healthcare Professional Communication on approved dosing regimens for Accord Bivalirudin for Percutaneous Coronary Intervention (PCI), following reports of inappropriate use

This letter will provide guidance on the dosing regimen, administration instructions, safety concerns and suspected adverse reactions to HCPs for patients undergoing Percutaneous Coronary Intervention (PCI).

For Healthcare Professionals

Blenrep

GlaxoSmithKline UK

Cover Letter – Risk Minimisation Materials

This letter outlines the risk minimisation materials developed to explain the corneal adverse reactions that may occur with belantamab mafodotin treatment and to provide monitoring and management guidance.

For Healthcare Professionals

Eye Care Evaluation guide for Physicians and Eye Care Professionals

This guide provides instructions to facilitate communication between prescribers and eye care professionals for corneal monitoring and management of patients receiving treatment with belantamab mafodotin.

For Healthcare Professionals

Important Information for Eye Care Professionals: Corneal Adverse Reactions

This guide is to provide eye care professionals with an overview of corneal adverse reactions that may occur with belantamab mafodotin treatment and to explain the important role of eye care professionals in the monitoring and management of patients receiving belantamab mafodotin

For Healthcare Professionals

Important Information for Physicians: Management of Corneal Adverse Reactions

This guide is to provide healthcare professionals with an overview of corneal adverse reactions that may occur with belantamab mafodotin treatment and guidance regarding supportive care and dose modifications to manage corneal adverse reactions

For Healthcare Professionals

Patient guide: Important information on Understanding the Vision and Eye Changes with treatment

This guide for patients provides an overview of the vision and eye changes that may occur with belantamab mafodotin treatment.

For Healthcare Professionals

Patient Wallet Card

This patient wallet card should be given to all patients to record their care team contact details. Patients should carry this card with them at all times.

Pharmacy Eye Drop wallet Card

This eye drop wallet card should be given to all patients to present to their pharmacist who will help provide preservative-free artificial tears eye drops. Patients should be carry this card with them at all times

Blincyto

Amgen Ltd

BLINCYTO Guide for Nurses

This educational brochure contains important information regarding the administration of BLINCYTO and the risks of medication errors and neurologic events. This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks and therefore it is advised to be read carefully before administering the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441

For Healthcare Professionals

BLINCYTO Guide for Patients and Caregivers

This educational brochure contains important information you should know before receiving BLINCYTO. This educational material is essential to ensure the safe and effective use of the drug and appropriate management of the important selected risks. Please read it carefully before taking the medicinal product. To request a copy of this guide, please contact Amgen Medical Information on +44 (0) 1223 436441

BLINCYTO Guide for Pharmacists

This educational brochure contains important information regarding the reconstitution and preparation procedures for blinatumomab. To ensure the safe and effective use of the medicinal product and appropriate management of the important selected risks, please carefully read this material before reconstituting and preparing of the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441

For Healthcare Professionals

BLINCYTO Guide for Physicians

This educational brochure contains important information regarding the administration of BLINCYTO and the risks of medication errors and neurologic events. This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks and therefore it is advised to be read carefully before prescribing and administering the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441

For Healthcare Professionals

BLINCYTO Patient Alert Card

This BLINCYTO patient alert card contains a warning message for HCPs that the patient is using BLINCYTO, includes contact details of the BLINCYTO prescriber and treatment start date, and information on the importance of reporting ADRs. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441

Bosentan

Cipla EU Ltd

Bosentan 62.5 mg and 125 mg film-coated tablets Prescribers guide

This Prescriber’s Guide provides a summary of the most important safety information you should know about bosentan and the following important risks associated with bosentan treatment and how to minimise them

For Healthcare Professionals

Patient card - Bosentan 62.5mg and 125mg film‐coated Tablets

Important Safety Alerts for Patients taking Bosentan Tablets (bosentan)

For Healthcare Professionals

Aurobindo Pharma - Milpharm Ltd.

Bosentan Milpharm - Patient Alert Card

Important Safety Alerts for Patients taking Bosentan Milpharm

Mylan

Bosentan Patient Alert Card

Important Safety Alerts for Patients taking Bosentan Mylan (bosentan)

Accord Healthcare Limited

Bosentan Patient Alert Card

Important Safety Alerts for Patients taking Bosentan Accord (bosentan)

Zentiva

Bosentan- Patient Alert Guide

This card contains important information about bosentan. Please read this card carefully before starting your treatment with bosentan. For hard copies please contact our medical information department on 0800 090 2408 or email [email protected]

Dr. Reddy's Laboratories (UK) Ltd

Braltus

Teva UK Limited

Risk Minimisation Information on Potential Risk of Medication Errors - Guide for HCPs

This educational guide is provided to highlight and minimise the potential risk of prescribing and administration errors (medication errors) due to the differences between Braltus (tiotropium bromide) and the originator product Spiriva® HandiHaler® (tiotropium bromide) with respect to the pre-metered dose.

For Healthcare Professionals

Brancico

Zentiva

Brancico XL 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets Educational material for health care professionals

Educational material for health care professionals Brancico XL 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets For hard copies please contact our medical information department at 0800 090 2408 or email [email protected]

For Healthcare Professionals

Bronchitol

Pharmaxis Europe Limited

Bronchitol Healthcare Professional Leaflet

Bronchitol Healthcare Professional Leaflet

For Healthcare Professionals